Trevi Therapeutics trial analysis ‘best case outcome,’ says Needham

Needham analyst Serge Belanger says Trevi Therapeutics (TRVI)’ Phase 2b CORAL trial evaluating Haduvio for idiopathic pulmonary fibrosis cough underwent a successful sample-size re-estimation analysis which determined the study could continue with no changes to the originally-planned sample size. This is the “best case outcome” of the trial’s analysis given that the study could have been halted due to futility or required additional patients, the analyst tells investors in a research note. The firm says there are two takeaways for this outcome, both of which are “de-risking” for the trial readout: the treatment effect size and study dropouts are in-line with original statistical powering assumptions. It keeps a Buy rating on Trevi with an $8 price target The stock in midday trading is up 70%, or $1.75, to $4.24.